These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24956626)

  • 1. [Clinical usage and future prospective of guidelines in treatment of hematological malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2014 May; 41(5):558-9. PubMed ID: 24956626
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hematologic Malignancies/Pediatric Malignancies Current Guidelines of Clinical Management and Drug Therapy for Hematological Malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2019 May; 46(5):859-861. PubMed ID: 31189804
    [No Abstract]   [Full Text] [Related]  

  • 3. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-1. Follicular lymphoma (FL).
    Izutsu K
    Int J Hematol; 2019 Jul; 110(1):11-19. PubMed ID: 31172373
    [No Abstract]   [Full Text] [Related]  

  • 4. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-6. Burkitt lymphoma (BL).
    Ishizawa K
    Int J Hematol; 2019 Sep; 110(3):265-271. PubMed ID: 31297687
    [No Abstract]   [Full Text] [Related]  

  • 5. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM).
    Iida S; Ishida T; Murakami H; Ozaki S; Abe M; Hata H; Shimazaki C
    Int J Hematol; 2019 May; 109(5):509-538. PubMed ID: 30949913
    [No Abstract]   [Full Text] [Related]  

  • 6. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-2. Related disorders of multiple myeloma.
    Iida S; Shimazaki C; Abe M; Nakaseko C
    Int J Hematol; 2019 Jun; 109(6):633-640. PubMed ID: 30963472
    [No Abstract]   [Full Text] [Related]  

  • 7. Future of cord blood for oncology uses.
    Brunstein CG; Weisdorf DJ
    Bone Marrow Transplant; 2009 Nov; 44(10):699-707. PubMed ID: 19802022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A protocol for the evaluation and treatment of oral mucositis in patients with hematological malignancies.
    Puyalt Casado M; Jiménez Martinez C; Chimenos Küstner E; López López J; Juliá A
    Med Oral; 2003; 8(1):10-8. PubMed ID: 12556718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the quality of clinical guidelines. Linking decisions to medical evidence.
    Djulbegovic B; Hadley T
    Oncology (Williston Park); 1998 Nov; 12(11A):310-4. PubMed ID: 10028514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WT1 peptide vaccination for the treatment of hematological malignancies: the present status and future direction.
    Oka Y; Tsuboi A; Shirakata T; Hosen N; Nishida S; Oji Y; Sugiyama H
    Rinsho Ketsueki; 2009 May; 50(5):352-7. PubMed ID: 19483394
    [No Abstract]   [Full Text] [Related]  

  • 11. [Evaluate the role of the guidelines from the development of "Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers" in China].
    Huang XJ
    Zhonghua Nei Ke Za Zhi; 2017 Jun; 56(6):393-394. PubMed ID: 28592035
    [No Abstract]   [Full Text] [Related]  

  • 12. [Undefined invasive fungal disease: a perspectie from the Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers].
    Hu J
    Zhonghua Nei Ke Za Zhi; 2017 Jun; 56(6):395-397. PubMed ID: 28592036
    [No Abstract]   [Full Text] [Related]  

  • 13. Hematologic malignancies and thrombosis.
    Elice F; Rodeghiero F
    Thromb Res; 2012 Mar; 129(3):360-6. PubMed ID: 22197450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monoclonal antibodies in the treatment of hematological malignancies].
    Itälä M
    Duodecim; 2002; 118(16):1647-56. PubMed ID: 12271942
    [No Abstract]   [Full Text] [Related]  

  • 15. Roundtable discussion: Incorporating bone marrow transplantation into NCCN guidelines.
    Vaughan WP; Silver SM; Beatty PG; Tallman MS
    Oncology (Williston Park); 1998 Nov; 12(11A):390-2. PubMed ID: 10028522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cellular immunotherapy for hematological malignancies].
    Yasukawa M
    Rinsho Ketsueki; 2008 Oct; 49(10):1460-71. PubMed ID: 18833930
    [No Abstract]   [Full Text] [Related]  

  • 17. Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?
    Chengappa M; Desai A; Go R; Poonacha T
    Oncology (Williston Park); 2021 Jul; 35(7):390-396. PubMed ID: 34270186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The progress of targeted therapy of hematological malignancies in recent 10 years].
    Wang L; Shen ZX
    Zhonghua Nei Ke Za Zhi; 2013 Feb; 52(2):121-3. PubMed ID: 23967604
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hematopoietic stem cell transplantation for the treatment of hematological malignancies].
    Okamoto S
    Rinsho Ketsueki; 2014 Feb; 55(2):160-9. PubMed ID: 24598182
    [No Abstract]   [Full Text] [Related]  

  • 20. [Front line of molecular-targeted therapy for hematological malignancies].
    Kizaki M
    Rinsho Byori; 2013 Mar; 61(3):283-90. PubMed ID: 23785799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.